CD8A and type 1 diabetes mellitus: To understand the clinical relevance of this finding, we compared the time to diagnosis with stage 3 T1D in teplizumab-treated patients with CD127 expression below (low MFI) and above the median expression of CD127 on EMRA CD8+ T cells from placebo-treated patients at 3 and 18 months (Figure 6, D–F).